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Abstract
The evolution of antimicrobial resistance generally occurs in an environment where antimicro-
bial concentration is variable, which has dramatic consequences on the microorganisms’ fitness
landscape, and thus on the evolution of resistance.
We investigate the effect of these time-varying patterns of selection within a stochastic model.
We consider a homogeneous microbial population of fixed size subjected to periodic alternations
of phases of absence and presence of an antimicrobial that stops growth. Combining analyti-
cal approaches and stochastic simulations, we quantify how the time necessary for fit resistant
bacteria to take over the microbial population depends on the alternation period. We demon-
strate that fast alternations strongly accelerate the evolution of resistance, reaching a plateau
for sufficiently small periods. Furthermore, this acceleration is stronger in larger populations.
For asymmetric alternations, featuring a different duration of the phases with and without an-
timicrobial, we shed light on the existence of a minimum for the time taken by the population
to fully evolve resistance. The corresponding dramatic acceleration of the evolution of antimi-
crobial resistance likely occurs in realistic situations, and may have an important impact both
in clinical and experimental situations.
Introduction
The discovery of antibiotics and antivirals has constituted one of the greatest medical advances
of the twentieth century, allowing many major infectious diseases to be treated. However, with
the increasing use of antimicrobials, pathogenic microorganisms tend to become resistant to
these drugs. Antimicrobial resistance has become a major and urgent problem of public health
worldwide [1, 2].
Mutations that confer antimicrobial resistance are often associated with a fitness cost, i.e. a
slower reproduction [3–5]. Indeed, the acquisition of resistance generally involves either a mod-
ification of the molecular target of the antimicrobial, which often alters its biological function,
or the production of specific proteins, which entails a metabolic cost [4]. However, resistant
microorganisms frequently acquire subsequent mutations that compensate for the initial cost
of resistance. These microorganisms are called “resistant-compensated” [6–9]. The acquisi-
tion of resistance is therefore often irreversible, even if the antimicrobial is removed from the
environment [4, 6].
In the absence of antimicrobial, the adaptive landscape of the microorganism, which repre-
sents its fitness (i.e. its reproduction rate) as a function of its genotype, involves a valley, since
the first resistance mutation decreases fitness, while compensatory mutations increase it. How-
ever, this fitness valley, which exists in the absence of antimicrobial, disappears above a certain
concentration of antimicrobial, as the growth of the antimicrobial-sensitive microorganism is
impaired. Thus, the adaptive landscape of the microorganism depends drastically on whether
the antimicrobial is present or absent. Taking into account this type of interaction between
genotype and environment constitutes a fundamental problem, even though most experiments
have traditionally focused on comparing different mutants in a unique environment [10]. In par-
ticular, recent theoretical analyses show that variable adaptive landscapes can have a dramatic
evolutionary impact [11–15].
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How do the timescales of evolution and variation in the adaptive landscape compare and
interact? What is the impact of the time variability of the adaptive landscape on the evolution
of antimicrobial resistance? In order to answer these questions, we construct a minimal model
retaining the fundamental aspects of antimicrobial resistance evolution. Focusing on the case
of a homogeneous microbial population of fixed size, we perform a complete stochastic study of
de novo resistance acquisition in the presence of periodic alternations of phases of absence and
presence of an antimicrobial that stops growth. These alternations can represent, for example, a
treatment where the concentration within the patient falls under the Minimum Inhibitory Con-
centration (MIC) between drug intakes [16]. Combining analytical and numerical approaches,
we show that these alternations substantially accelerate the evolution of resistance with respect
to the cases of continuous absence or continuous presence of antimicrobial, especially for larger
populations. We fully quantify this effect and shed light on the different regimes at play. For
asymmetric alternations, featuring a different duration of the phases with and without antimi-
crobial, we demonstrate the existence of a minimum for the time taken by the population to
fully evolve resistance, occurring when both phases have durations of the same order. This
realistic situation dramatically accelerates the evolution of resistance. Finally, we discuss the
implications of our findings, in particular regarding antimicrobial dosage.
Model
The action of an antimicrobial drug can be quantified by its MIC, the minimum concentration
that stops the growth of a microbial population [4]. We focus on biostatic antimicrobials, which
stop microbial growth (vs. biocidal antimicrobials, which kill microorganisms). We model the
action of the antimicrobial in a binary way: below the MIC (“absence of antimicrobial”), growth
is not affected, while above it (“presence of antimicrobial”), sensitive microorganisms cannot
grow at all. The usual steepness of pharmacodynamic curves around the MIC [16] justifies our
simple binary approximation, and we also present an analysis of the robustness of this hypothesis
(Supplementary Material, Section 6). Within this binary approximation, there are two adaptive
landscapes. Assuming that the drug fully stops the growth of sensitive microorganisms, but
does not affect that of resistant ones, and considering compensatory mutations that fully restore
fitness, these two adaptive landscapes can be described by a single parameter δ, representing
the fitness cost of resistance (Fig. 1A). We focus on asexual microorganisms, and fitness simply
denotes the division rate of these organisms. The fitness of sensitive microorganisms in the
absence of antimicrobials is taken as reference. In this framework, we investigate the impact
of a periodic presence of antimicrobial, assuming that the process starts without antimicrobial
(Fig. 1B-C).
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Figure 1: Model. (A) Adaptive landscapes in the presence and in the absence of antimicrobial.
Genotypes are indicated by the number of mutations from the sensitive microorganism, and by
initials: S: sensitive; R: resistant; C: resistant-compensated.
(B) and (C) Periodic presence of antimicrobial, and impact on the fitness of S (sensitive) mi-
croorganisms: (B) Symmetric alternations; (C) Asymmetric alternations.
We denote by µ1 and µ2 the mutation rates (or mutation probabilities upon each division)
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for the mutation from S to R and for the one from R to C, respectively. In several actual
situations, the effective mutation rate towards compensation tends to be higher than the one
towards the return to sensitivity, since multiple mutations can compensate for the initial cost of
resistance [7, 8, 17]. Therefore, we do not take into account back-mutations. Still because of the
abundance of possible compensatory mutations, generally µ1 ≪ µ2 [7, 18]. We present general
analytical results as a function of µ1 and µ2, and analyze in more detail the limit µ1 ≪ µ2,
especially in simulations. All notations introduced are summed up in Table S1.
We focus on a homogeneous microbial population of fixed size N , which can thus be described
in the framework of the Moran process [19, 20], where fitnesses are relative (see Supplementary
Material, Section 2 and Fig. S1). Assuming a constant size simplifies the analytical treatment
and is appropriate for instance to describe turbidostat experiments, where the dilution rate is
adjusted so that turbidity (and hence population size) is constant [21]. If a population only
features sensitive individuals (with zero fitness) in the presence of antimicrobial, we consider
that no division occurs, and the population remains static. We always express time in number
of generations, which corresponds (unless no cell can divide) to the number of Moran steps
divided by the population size N .
Throughout, we start from a microbial population where all individuals are S (sensitive), and
we focus on the time tfC it takes for the C (resistant-compensated) type to fix in the population,
i.e. to take over the population. Then, the population has fully evolved resistance de novo.
Results
A periodic presence of antimicrobial can drive resistance evolution
In this section, we study how alternations of absence and presence of antimicrobial can drive
the de novo evolution of resistance. We present analytical predictions for the time needed for
the population to evolve resistance, and then we compare them to numerical simulation results.
We first focus on the rare mutation regime Nµ1 ≪ 1, where at most one mutant lineage
exists in the population at each given time. The frequent mutation regime is briefly discussed,
and more detail regarding the appropriate deterministic treatment in this regime is given in
Supplementary Material, Section 3. Here, we consider the case of symmetric alternations with
period T (Fig. 1B). Asymmetric alternations (Fig. 1C) will be discussed later.
Time needed for resistant microorganisms to start growing
Resistant (R) mutants can only appear during phases without antimicrobial. Indeed, mutations
occur upon division, and sensitive (S) bacteria cannot divide in the presence of antimicrobial
(Fig. 1). However, R mutants are less fit than S individuals without antimicrobial. Hence, the
lineage of an R mutant will very likely disappear, unless it survives until the next addition of
antimicrobial. More precisely, without antimicrobial, the fixation probability pSR of a single R
mutant with fitness 1 − δ, in a population of size N where all other individuals are of type S
and have fitness 1, is ∼ 1/N if the mutation from S to R is effectively neutral (Nδ ≪ 1), and
∼ δe−Nδ if δ ≪ 1 and Nδ ≫ 1 [20]. Let us denote by τdR the average time an R lineage would
drift before going extinct without antimicrobial [20] (see Supplementary Material, Section 2).
If antimicrobial is added while R mutants exist in the population, i.e. within ∼ τdR after a
mutation event, then the R population will grow fast and fix, since S individuals cannot divide
with antimicrobial. Hence, each time antimicrobial is added, any R lineage that was destined
for extinction without antimicrobial but that survived until the addition of drug is rescued.
Through this phenomenon, periodic alternations of absence and presence of antimicrobial can
substantially accelerate resistance evolution: we will quantify this effect. Note that here, we
disregard the very few R lineages destined for fixation without antimicrobial, because we aim to
study the acceleration of resistance evolution due to the alternations. The spontaneous evolution
of resistance without antimicrobial is discussed and compared to our alternation-driven process
in the Supplementary Material, Section 4.
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It is crucial to calculate the average waiting time taR until an R lineage is rescued by the
addition of antimicrobial. Indeed, this constitutes the key step of alternation-driven resistance
takeover. Three timescales impact taR. The first one is the timescale of the environment, namely
the half-period T/2. The two other ones are intrinsic timescales of the evolution of the population
without antimicrobial: the average time between the appearance of two independent R mutants,
1/(Nµ1), and the average lifetime τ
d
R of the lineage of an R mutant destined for extinction
without antimicrobial. Note that τdR is generally quite short. Indeed, τ
d
R ≈ logN for large
N if δ = 0, and τdR decreases as δ increases, as deleterious R mutants are out-competed by S
microorganisms; for instance, τdR ≈ 2.6 generations if δ = 0.1 in the limit where N ≫ 1 and
Nδ ≫ 1 [20] (see Supplementary Information, Section 2). Hence, in the rare mutation regime,
τdR ≪ 1/(Nµ1). What matters is how the environment timescale T/2 compares to these two
evolution timescales (see Fig. 2A-C). Our arguments based on comparing average timescales are
approximate, but they yield explicit analytical predictions in each regime where timescales are
separated, which we then test through numerical simulations.
Figure 2: Alternation-driven evolution of antimicrobial resistance. (A-C) Sketches il-
lustrating the three different regimes for the half-period T/2 of the alternations of antimicrobial
absence (white) and presence (gray). The fraction of resistant (R) microorganisms in the pop-
ulation is plotted versus time (blue curves). R mutants can only appear without antimicrobial.
(A) T/2 ≪ τdR, where τdR is the average extinction time of the lineage of an R mutant without
antimicrobial. The first R lineage that appears is expected to live until the next addition of
antimicrobial and is then rescued. (B) τdR ≪ T/2 ≪ 1/(Nµ1), where 1/(Nµ1) is the aver-
age time between the appearance of two independent R mutants without antimicrobial. (C)
T/2≫ 1/(Nµ1). In (B) and (C), not all R lineages live until the next addition of antimicrobial,
and in (C) multiple R lineages arise within a half-period. (D) Example of a simulation run.
The fractions of S, R and C microorganisms are plotted versus time. Inset: end of the process,
with full resistance evolution. As in (A-C), antimicrobial is present during the gray-shaded time
intervals (shown only in the inset given their duration). Parameters: µ1 = 10
−5, µ2 = 10
−3,
δ = 0.1, N = 102 and T = 50 (belonging to regime B).
(A) If T/2 ≪ τdR (Fig. 2A): The lineage of the first R mutant that appears is likely to still
exist upon the next addition of antimicrobial, and to be rescued, which yields taR = 2/(Nµ1).
Indeed, mutations from S to R can only occur without antimicrobial, i.e. half of the time.
(B) If τdR ≪ T/2 ≪ 1/(Nµ1) (Fig. 2B): At most one mutation yielding an R individual is
expected within each half-period. The lineage of this mutant is likely to survive until the next
addition of antimicrobial only if the mutant appeared within the last ∼ τdR preceding it, which
has a probability p = 2τdR/T . Hence, t
a
R = 2/(Nµ1p) = T/(Nµ1τ
d
R).
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(C) If T/2≫ 1/(Nµ1) (Fig. 2C): Since the half-period is much larger than the time 1/(Nµ1)
between the appearance of two independent mutants without antimicrobial, several appearances
and extinctions of R lineages are expected within one half-period. Hence, the probability that
a lineage of R exists upon a given addition of antimicrobial is q = Nµ1τ
d
R, which corresponds
to the fraction of time during which R mutants are present in the phases without antimicrobial.
Specifically, q is the ratio of the average lifetime of the lineage of an R mutant destined for
extinction without antimicrobial to the average time between the appearance of two independent
R mutants without antimicrobial. Since additions of antimicrobial occur every T , we have
taR = T/q = T/(Nµ1τ
d
R), which is the same as in case (B). In fact, the demonstration presented
for case (C) also holds for case (B).
In conclusion, we obtain
taR =
T
Nµ1min
(
τdR, T/2
) . (1)
Hence, if T/2≪ τdR, taR is independent from the period T of alternations, while if T/2≫ τdR, taR
is proportional to T .
Time needed for the population to fully evolve resistance
We are interested in the average time tfC it takes for the population to fully evolve resistance, i.e.
for the C (resistant-compensated) type to fix. An example of the process is shown in Fig. 2D.
It takes on average taR for R mutants to be rescued by the addition of antimicrobial. Then they
rapidly grow, since S individuals cannot divide. If the phase with antimicrobial is long enough,
R mutants take over during this phase, with a probability 1 and an average fixation timescale
τ fR ≈ logN forN ≫ 1 [20] (see Supplementary Material, Section 2). If T/2≪ τ fR, fixation cannot
occur within a single half-period, and the R lineage will drift longer, but its extinction remains
very unlikely. Indeed, while R individuals are the only ones that can divide with antimicrobial,
we assume that they experience only a minor disadvantage without antimicrobial (1 − δ vs. 1,
generally with δ ≪ 1 [4], see Fig. 1A). Hence, if T/2≪ τ fR, and neglecting changes in frequencies
in the absence of antimicrobial, R mutants will take ∼2τ fR to fix.
Once the R type has fixed in the population, the appearance and eventual fixation of C
mutants are independent from the presence of antimicrobial, since only S microorganisms are
affected by it (see Fig. 1A). The first C mutant whose lineage will fix takes an average time
taC = 1/(Nµ2 pRC) to appear once R has fixed, where pRC is the fixation probability of a single
C mutant in a population of size N where all other individuals are of type R. In particular, if
Nδ ≪ 1 then pRC = 1/N , and if δ ≪ 1 and Nδ ≫ 1 then pRC ≈ δ [20] (see Supplementary
Material, Section 2). The final step is the fixation of this successful C mutant, which will take
an average time τ fC, of order N in the effectively neutral regime Nδ ≪ 1, and shorter for larger
δ given the selective advantage of C over R [20] (see Supplementary Material, Section 2). Note
that we have assumed for simplicity that the fixation of R occurs before the appearance of the
first successful C mutant, which is true if taC ≫ τ fR, i.e. 1/(Nµ2 pRC) ≫ logN . This condition
is satisfied if the second mutation is sufficiently rare. Otherwise, our calculation will slightly
overestimate the actual result.
Combining the previous results yields
tfC ≈ taR + τ fR + taC + τ fC , (2)
where taR is given by Eq. 1, while t
a
C = 1/(Nµ2 pRC), and τ
f
R ≈ logN and τ fC . N . In the rare
mutation regime, the contribution of the two fixation times τ fR and τ
f
C will be negligible. If in
addition µ1 ≪ µ2, which is realistic (cf. Methods), then tfC will be dominated by taR. If µ1 ≈ µ2,
tfC will be dominated by t
a
R if T > max
(
2τdR, τ
d
R/pRC
)
. Indeed, if T < 2τdR, using Eq. 1 shows
that the condition taR > t
a
C is then equivalent to pRC > 1/2, which cannot be satisfied for δ ≪ 1.
Hence, T > 2τdR is necessary to have t
a
R > t
a
C. But if T > 2τ
d
R and µ1 ≈ µ2, the condition taR > taC
is equivalent to T > τdR/pRC. Beyond the regime T > max
(
2τdR, τ
d
R/pRC
)
, the contribution of
taC to t
f
C will be important.
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Comparison of analytical predictions and simulation results
Fig. 3A shows simulation results for the average total fixation time tfC of C individuals in the
population. This time is plotted as a function of the period T of alternations for different
population sizes N . As predicted above (see Eq. 1), we observe two regimes delimited by
T = 2τdR. If T ≪ 2τdR, tfC does not depend on T , while if T ≫ 2τdR, it depends linearly on T .
In Fig. 3A, we also plot our analytical prediction from Eqs. 1 and 2 in these two regimes (solid
lines). The agreement with our simulated data is excellent for small and intermediate values of
T , without any adjustable parameter. Interestingly, the transition between these two regimes
occurs for periods of about 5 generations, which would correspond to a few hours for typical
bacteria, thus highlighting the practical importance of these two regimes. In Fig. 3A, the smallest
values reported for tfC are of order 100 generations, corresponding to a few days, and are thus
relevant to an actual treatment, while some other values are larger than the timescales involved
in a treatment. Here, we quantitatively analyze the phenomena for a wide range of parameters.
A more detailed comparison to actual situations, employing realistic values of population sizes
and mutation rates, is presented in the Discussion.
Figure 3: Impact of symmetric alternations. Fixation time tfC of C (resistant-compensated)
individuals in a population of N individuals subjected to symmetric alternations of absence and
presence of antimicrobial with period T . Data points correspond to the average of simulation
results, and error bars (often smaller than markers) represent 95% confidence intervals. 2 to
104 replicate simulations were performed in each case (the smallest numbers of replicates were
used for the largest populations, whose evolution is quasi-deterministic). In both panels, solid
lines correspond to our analytical predictions in each regime. Parameter values: µ1 = 10
−5,
µ2 = 10
−3, and δ = 0.1. (A) tfC as function of T . Vertical dashed line: T = 2τ
d
R. (B) t
f
C
as function of N . Left vertical dashed line: limit of the neutral regime, N = 1/δ. Right
vertical dashed line: limit of the deterministic regime, N = 1/µ1. Horizontal purple line:
analytical prediction for valley crossing by neutral tunneling in the presence of alternations (see
Supplementary Material, Section 4). Black lines: analytical predictions for fitness valley crossing
times in the absence of alternations (see Supplementary Material, Section 4).
Importantly, Fig. 3A shows that tfC reaches a plateau for small N and large T , which is
not predicted by our analysis of the alternation-driven evolution of resistance. This plateau
corresponds to the spontaneous fitness valley crossing process [22], through which resistance
mutations appear and fix in the absence of drug. Note that such a plateau would also be
reached for larger N , but for periods T longer than those considered in Fig. 3A (see Fig. 3B,
black lines). What ultimately matters is the shortest process among the alternation-driven one
and the spontaneous valley-crossing one. In Fig. 3A, horizontal solid lines at large T represent
our analytical predictions for the valley-crossing time (see Supplementary Material, Section 4).
Fig. 3B shows simulation results for tfC as function of N for different T . Again, solid lines rep-
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resent our analytical predictions from Eqs. 1 and 2, yielding excellent agreement for intermediate
values of N , and for small ones at small T . In other regimes, resistance evolution is achieved by
spontaneous valley crossing. In the limit T →∞ of continuous absence of antimicrobial (black
data points in Fig. 3B), only valley crossing can occur, and the black solid lines correspond to
our analytical predictions for this process (see Supplementary Material, Section 4).
Until now, we focused on the rare mutation regime. In the large-population, frequent-
mutation regime N ≫ 1/µ1 ≫ 1, the dynamics of the population can be well-approximated
by a deterministic model with replicator-mutator differential equations [23, 24] (see Supplemen-
tary Material, Section 3). Then, several lineages of mutants can coexist. If T/2 ≫ 1/(Nµ1),
it is almost certain that some R mutants exist in the population upon the first addition of
antimicrobial, which entails taR = T/2. The horizontal purple solid line plotted at large T in
Fig. 3A, and the horizontal solid lines at large N in Fig. 3B, both correspond to this determinis-
tic prediction. In the Supplementary Material, Section 3, we study the deterministic limit of our
stochastic model, and demonstrate that it matches the results obtained in Fig. 3A for N = 105
and N = 106 over the whole range of T (see Fig. S2).
The comparison to the spontaneous fitness valley crossing process (Fig. 3B, black curve and
Supplementary Material, Section 4) demonstrates that periodic alternations of absence and pres-
ence of antimicrobial can dramatically accelerate resistance evolution compared to continuous
absence of antimicrobial. Recall that within our model, sensitive microorganisms cannot divide
with antimicrobial, so resistance cannot evolve at all in continuous presence of antimicrobial.
Another possible comparison would be to a continuous presence of a low dose of antimicrobial
(below the MIC), but this goes beyond our binary model of antimicrobial action (see Supplemen-
tary Information, Section 6 for a discussion of the domain of validity of this model). Alternations
are really essential: R mutants appear without antimicrobial, and each addition of antimicrobial
rescues the existing R lineages that would be destined to extinction without antimicrobial.
Asymmetric alternations
We now turn to the more general case of asymmetric alternations of phases of absence and
presence of antimicrobial, with respective durations T1 and T2, and T = T1 + T2 (see Fig. 1C).
The average time taR when R mutants first exist in the presence of antimicrobial, and start
growing, can be obtained by a straightforward generalization of the symmetric alternation case
Eq. 1. What matters is how the duration T1 of the phase without antimicrobial, where S
individuals can divide and mutate, compares to the average time τdR an R lineage would drift
before extinction without antimicrobial. If T1 ≪ τdR, the first R mutant takes an average
time T/(Nµ1T1) to appear, and is likely to be rescued by the next addition of antimicrobial.
If T1 ≫ τdR, the fraction of time during which R mutants are present in the phases without
antimicrobial is Nµ1τ
d
R, and antimicrobial is added every T , so t
a
R = T/(Nµ1τ
d
R). Hence, we
obtain
taR =
T
Nµ1min(τdR, T1)
. (3)
Once the R mutants have taken over the population, the appearance and fixation of C
mutants is not affected by the alternations. Hence, Eq. 2 holds for asymmetric alternations,
with taR given by Eq. 3. In the rare mutation regime, if µ1 ≪ µ2, then tfC will be dominated by
taR, and if µ1 ≈ µ2, then tfC will be dominated by taR if T > min
(
τdR, T1
)
/pRC, where pRC is the
fixation probability of a single C mutant in a population of R individuals.
Fig. 4A shows simulation results for tfC as a function of the duration T1 of the phases without
antimicrobial, for different values of the duration T2 of the phases with antimicrobial. As
predicted above, we observe a transition at T1 = τ
d
R, and different behaviors depending whether
T2 ≪ τ fR or T2 ≫ τ fR. Our analytical predictions from Eqs. 2 and 3 are plotted in Fig. 4A
in the various regimes (solid lines), and are in excellent agreement with the simulation data.
The plateau of tfC at large T1 corresponds to spontaneous valley crossing, and the analytical
prediction (see Supplementary Material, Section 4) is plotted in black in Fig. 4A.
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Figure 4: Asymmetric alternations. Fixation time tfC of C individuals in a population sub-
jected to asymmetric alternations of absence and presence of antimicrobial (respective durations:
T1 and T2). Data points correspond to the average of simulation results (over 10 to 10
3 repli-
cates), and error bars (sometimes smaller than markers) represent 95% confidence intervals. In
both panels, solid lines correspond to our analytical predictions in each regime. In particular,
black lines are analytical predictions for fitness valley crossing times in the absence of alterna-
tions (see Supplementary Material, Section 4). Parameter values: µ1 = 10
−5, µ2 = 10
−3, δ = 0.1
and N = 103. (A) tfC as function of T1 for different T2. Dashed line: T1 = τ
d
R. (B) t
f
C as function
of T2 for different T1. Dashed line: T2 = τ
f
R.
For T2 ≫ τ fR, Fig. 4A shows that tfC features a striking minimum, which gets higher but
wider for longer T2. This can be fully understood from our analytical predictions. Indeed, when
T1 is varied starting from small values at fixed T2 ≫ τ fR, different regimes can be distinguished:
• When T1 ≪ τdR
(
. τ fR ≪ T2
)
, Eq. 3 yields taR = T/(Nµ1T1) ≈ T2/(Nµ1T1) ∝ 1/T1.
• When τdR ≪ T1 ≪ T2, Eq. 3 gives taR = T/(Nµ1τdR) ≈ T2/(Nµ1τdR), which is independent
from T1.
• As T1 reaches and exceeds T2, the law taR = T/(Nµ1τdR) still holds. It yields taR ≈
T1/(Nµ1τ
d
R) ∝ T1 when τdR ≪ T2 ≪ T1.
Hence, the minimum of taR is T2/(Nµ1τ
d
R) ∝ T2 and is attained for τdR ≪ T1 ≪ T2: it gets higher
but wider for larger T2.
In the opposite regime where T2 ≪ τdR . τ fR, Fig. 4A shows that tfC also features a minimum
as a function of T1:
• When T1 ≪ T2 ≪ τdR, Eq. 3 yields taR = T/(Nµ1T1) ≈ T2/(Nµ1T1) ∝ 1/T1.
• When T2 ≪ T1 ≪ τdR, the same law gives taR = T/(Nµ1T1) ≈ 1/(Nµ1), which is indepen-
dent from T1.
• When T2 ≪ τdR ≪ T1, R lineages eventually tend to go extinct, even once they have started
growing thanks to an addition of antimicrobial (see Supplementary Material, Section 5
and Fig. S3B). Then, alternations do not accelerate resistance evolution, and spontaneous
valley crossing dominates (black horizontal line in Fig 4A).
Hence, the minimum of taR is 1/(Nµ1) and is attained for T2 ≪ T1 ≪ τdR: then, the first R
mutant that appears is likely to be rescued by the next addition of antimicrobial, thus driving
the complete evolution of resistance in the population. For T2 ≤ T1 ≪ τdR, taR is between once
and twice this minimum value.
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A similar analysis can be conducted if T2 is varied at fixed T1 (Fig. 4B); it is presented in
the Supplementary Material, Section 5. In a nutshell, for asymmetric alternations, a striking
minimum for the time of full evolution of resistance by a population occurs when both phases
have durations of the same order. Interestingly, the minimum generally occurs when the phases
of antimicrobial presence are shorter than those of absence, i.e. T2 ≤ T1 (except if T2 ≫ τdR).
In addition to this minimum, Fig. 4 also shows a regime of parameters, when T1 ≪ T2 and
T1 ≪ τdR, where the evolution of resistance actually takes longer than fitness valley crossing
in the absence of antimicrobial (black lines in Fig. 4). Comparing the timescales involved (see
Supplementary Material, Section 4) shows that in this regime, if T2 ≫ T1δ/µ2, the alternation-
driven process is faster than the valley-crossing process in the presence of alternations, and
thus dominates, but it is slower than the valley-crossing process in the absence of antimicrobial.
Hence, in this case, the drug actually slows down the evolution of resistance. Qualitatively, this
is because the antimicrobial prevents mutants from arising when it is present.
Discussion
Main conclusions
Because of the generic initial fitness cost of resistance mutations, alternations of phases of absence
and presence of antimicrobial induce a dramatic time variability of the adaptive landscape
associated to resistance evolution, which alternates back and forth from a fitness valley to an
ascending landscape. Using a general and minimal theoretical model which retains the key
biological ingredients, we have shed light on the quantitative implications of these time-varying
patterns of selection on the time it takes for resistance to fully evolve de novo in a homogeneous
microbial population of fixed size. Combining analytical approaches and simulations, we showed
that resistance evolution can be driven by periodic alternations of phases of absence and presence
of an antimicrobial that stops growth. Indeed, the addition of antimicrobial is able to rescue
resistant lineages that were destined to go extinct without antimicrobial.
We found that fast alternations strongly accelerate the evolution of resistance. In the limit
of short alternation periods, the very first resistant mutant that appears is likely to ultimately
lead to full resistance of the population, as it will generally be rescued by the next addition of
antimicrobial before going extinct, which would be its most likely fate without antimicrobial.
For larger periods T , the time needed for resistance to evolve increases linearly with T , until
it reaches the spontaneous valley-crossing time with alternations, which constitutes an upper
bound. Our complete stochastic model allowed us to investigate the impact of population size N ,
beyond the limit N ≫ 1/µ1 addressed by deterministic models. We showed that the acceleration
of resistance evolution is stronger for larger populations, eventually reaching a plateau in the
deterministic limit. Over a large range of intermediate parameters, the time needed for the
population to fully evolve resistance scales as T/N . These results are summed up in Fig. 5A.
For asymmetric alternations, featuring different durations T1 and T2 of the phases of absence
and presence of antimicrobial, we have shed light on the existence of a minimum for the time
taken by the population to fully evolve resistance. This striking minimum occurs when both
phases have durations of the same order, generally with T1 ≤ T2. Moreover, the minimum value
reached for the time of resistance evolution decreases for shorter alternation periods. These
results are summed up in Fig. 5B.
Context and perspectives
Our approach is complementary to previous studies providing a detailed modeling of specific
treatments [16, 25–30]. Indeed, the majority of them [16, 25–28, 31, 32] neglect stochastic
effects, while they can have a crucial evolutionary impact [20, 33]. The deterministic approach is
appropriate if the number N of competing microbes satisfies Nµ1 ≫ 1, where µ1 is the mutation
rate [33, 34]. Such large sizes can be reached in some established infections [17], but microbial
populations go through very small bottleneck sizes (sometimes N ∼ 1−10 [35]) when an infection
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Figure 5: Heatmaps. Fixation time tfC of C individuals in a population of size N subjected
to periodic alternations of absence and presence of antimicrobial. Simulation data plotted in
Figs. 3A and 4A are linearly interpolated. Parameter values: µ1 = 10
−5, µ2 = 10
−3, δ = 0.1. (A)
Symmetric alternations: tfC as function of the period T and the population sizeN . Top horizontal
line: deterministic regime limitN = 1/µ1. Bottom horizontal line: neutral regime limitN = 1/δ.
Quasi-vertical curve: T = 2τdR. Diagonal line: T = N . Note that no data is shown for T/2 < 1/N
because of the discreteness of our model, which can only deal with timescales larger or equal
to the duration of one Moran step, i.e. 1/N generation. (B) Asymmetric alternations: tfC as
function of the durations T1 and T2 of the phases of absence and presence of antimicrobial.
Vertical line: T1 = τ
d
R. Horizontal line: T2 = τ
f
R. Diagonal line: T1 = T2. Here N = 10
3, so the
first resistant mutant appears after an average time T/(Nµ1T1) = 10
2 T/T1.
is transmitted. Moreover, established microbial populations are structured, even within a single
patient [36], and competition is local, which decreases the effective value of N . Some previous
studies did take stochasticity into account, but several did not include compensation of the cost
of resistance [37, 38], while others made specific epidemiological assumptions [29].
Given the usual steepness of pharmacodynamic curves [16], we have modeled the action of
a biostatic antimicrobial in a binary way, with no growth inhibition under the MIC and full
growth inhibition of S microorganisms above it (see Model). An analysis of the robustness of
this approximation is presented in the Supplementary Material, Section 6, showing that it is
appropriate if the rise time, i.e. the time needed for the fitness of sensitive microorganisms to
switch from a low value to a high value and vice-versa when antimicrobial is removed or added, is
short enough (see Fig. S4). Qualitatively, if this rise time is shorter than the other environmental
and evolutionary timescales at play, then the fitness versus time function is effectively binary.
Our model assumes that the size of the microbial population remains constant. While this
is realistic in some controlled experimental setups, e.g. turbidostats [21], microbial populations
involved in infections tend to grow, starting from a small transmission bottleneck, and the aim
of the antimicrobial treatment is to make them decrease in size and eventually go extinct. In the
case of biostatic antimicrobials, which prevent bacteria from growing, populations can go extinct
due to spontaneous and immune system-induced death. Our model with constant population
size should however be qualitatively relevant at the beginning and middle stages of a treatment
(i.e. sufficiently after transmission and before extinction). Constant population sizes facilitate
analytical calculations, and allowed us to fully quantify the impact of a periodic presence of
antimicrobial on resistance evolution, but it will be very interesting to extend our work to variable
population sizes [13, 39, 40]. This would allow us to model biocidal antimicrobials, and to include
effects such as antibiotic tolerance, which tend to precede resistance under intermittent antibiotic
exposure [41]. Another exciting extension would be to incorporate spatial structure [42–44] and
environment heterogeneity, in particular drug concentration gradients. Indeed, static gradients
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can strongly accelerate resistance evolution [45–48], and one may ask how this effect combines
with the temporal alternation-driven one investigated here. Besides, it would be interesting to
compare the impact of periodic alternations to that of random switches of the environment [11–
15].
Implications for clinical and experimental situations
The situation where the phases of absence and presence of antimicrobial have similar durations
(T1 ≈ T2) yields a dramatic acceleration of resistance evolution, and is unfortunately clinically
realistic. Indeed, a goal in treatment design is that the serum concentration of antimicrobial
exceeds the MIC for at least 40 to 50% of the time [49], which implies that actual treatments may
involve the alternations that most favor resistance evolution according to our results [16, 49].
Besides, bacteria divide on a timescale of about an hour (yielding a τdR of order of a few hours),
and antimicrobial is often taken every 8 to 12 hours in treatments by the oral route, so the
alternation period does not last for many generations: this is close to our worst-case scenario of
short symmetric periods.
In this worst case scenario, full de novo resistance evolution can result from the appearance
of the very first R mutant, which takes T/(Nµ1T1). Indeed, its lineage is likely to be rescued by
the next addition of antimicrobial. Under the conservative assumption that only one resistance
mutation is accessible, taking µ1 ∼ 10−10, which is the typical mutation probability per nu-
cleotide and per generation in Escherichia coli bacteria [50], and taking δ ∼ 0.1 [6], we find that
this duration is less than a day (∼ 10−20 generations) for N ∼ 109, and a few days for N ∼ 108,
numbers that can be reached in infections [5, 17]. For such large populations, the fixation of the
C (compensated) mutant will take more time, but once R is fixed (which takes ∼ 1 day after
the appearance of the first R mutant), C is very likely to fix even if the treatment is stopped.
This is due to the large number of compensatory mutations, which yields a much higher effective
mutation rate toward compensation than toward reversion to sensitivity [7, 8, 17]. In addition,
many mutations to resistance are often accessible, yielding higher effective µ1, e.g. µ1 ∼ 10−8
for rifampicin resistance in some wild isolates of E. coli [9], meaning that smaller populations
can also quickly become resistant in the presence of alternations. Recall that we are only con-
sidering de novo resistance evolution, without pre-existent resistant mutants, or other possible
sources of resistance, such as horizontal gene transfer, which would further accelerate resistance
acquisition.
In summary, an antimicrobial concentration that drops below the MIC between each intake
can dramatically favor de novo resistance evolution. More specifically, we showed that the worst
case occurs when T1 ≤ T2, which would be the case if the antimicrobial concentration drops below
the MIC relatively briefly before each new intake. Our results thus emphasize how important it
is to control for such apparently innocuous cases, and constitute a striking argument in favor of
the development of extended-release antimicrobial formulations [51].
While the parameter range that strongly accelerates resistance evolution should preferably
be avoided in clinical situations, it could be tested and harnessed in evolution experiments.
Again, these parameters are experimentally accessible. Controlled variations of antimicrobial
concentration are already used experimentally, in particular in morbidostat experiments [52],
where the population size is kept almost constant, which matches our model. In Ref. [52], a
dramatic and reproducible evolution of resistance was observed in ∼ 20 days when periodically
adjusting the drug concentration to constantly challenge E. coli bacteria. Given our results, it
would be interesting to test whether resistance evolution could be made even faster by adding
drug in a turbidostat with a fixed periodicity satisfying T1 ≤ T2 ≪ τdR.
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Supplementary Material
1 Table of notations
Notation Definition
S Sensitive microorganisms
R Resistant microorganisms
C Resistant-compensated microorganisms
T Period of the alternations of absence and presence of antimicrobial
T1 Duration of the phase without antimicrobial (for asymmetric alternations)
T2 Duration of the phase with antimicrobial (for asymmetric alternations)
N Population size
δ Fitness cost of antimicrobial resistance
µ1 Mutation rate from S to R
µ2 Mutation rate from R to C
tfC Total time of full resistance evolution (time until the C type fixes, starting from
a population of S individuals)
taR Average time when R individuals first exist in the presence of antimicrobial, start-
ing from a population of S individuals
taC Average time when the first C mutant whose lineage will fix appears, starting
from a population of R individuals
τdR Average lifetime of the lineage of a single R mutant, until it disappears, in a
population of S individuals, in the absence of antimicrobial
τ fR Average fixation time of the lineage of a single R mutant in a population of S
individuals, in the presence of antimicrobial
τ fC Average fixation time of the lineage of a single C mutant in a population of R
individuals
pSR Fixation probability of a single R mutant in a population of S individuals in the
absence of antimicrobial
pRC Fixation probability of a single C mutant in a population of R individuals
Table S1: Notations. This table lists the different notations introduced in the main text and
their meaning.
2 Fixation probabilities and fixation times in the Moran process
Here, we discuss in detail the fixation probabilities and mean fixation times in the Moran process,
which are used throughout the main text. These quantities are already known [20, 24], but we
present a derivation for the sake of pedagogy and completeness. Our derivation is based on the
general formalism of first passage times, and gives the same results as those obtained in the
literature, often using other methods [20, 24]. Next, we use the general expressions obtained to
express the various fixation probabilities and fixation times used in the main text.
2.1 The Moran process
The Moran model [19, 20] is a simple stochastic process used to describe the evolution of the
composition of asexual populations of finite and constant size. It allows one to incorporate
variety-increasing processes such as mutation and variety-reducing processes such as natural
selection.
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In the Moran model, at each time step, an individual is chosen at random to reproduce and
another one is chosen to die (see Figure S1). Hence, the total number of individuals in the
population stays constant. Note that we will consider that the same individual can be selected
to reproduce and die at the same step. Natural selection can be introduced by choosing the
individual that reproduces with a probability proportional to its fitness. To implement mutations
upon division, one can allow the offspring to switch type with a certain probability at each
step. When a mutant arises within the Moran model at constant fitness, its lineage can either
disappear or fix in the population, i.e. take over the whole population. The outcome is not fully
determined by fitness differences as in a deterministic case, but also by stochastic fluctuations,
also known as genetic drift. Here, we focus on the evolution of population composition under
genetic drift and selection alone. In the rare mutation regime, these processes are much faster
than the time between the occurrence of two mutations, so mutation can be neglected during
the process of fixation of one type. The Moran model allows us to compute explicit expressions
for quantities such as fixation probabilities and fixation times [20, 53] (see below).
Figure S1: Sketch of the Moran process. One step of the Moran process is represented in a
population with 8 individuals of 2 different types (different colors).
Let us consider a population of N individuals of two types A and B, which have fitnesses
fA and fB , respectively. We denote the number of A individuals by j. Thus N − j represents
the number of B individuals. Let us study the evolution of j at one step of the Moran process
(for an example, see Figure S1). The transition probabilities associated to the Moran process
read [20]: 

Πj→j+1 =
N − j
N
fAj
fAj + fB(N − j)
Πj→j−1 =
j
N
fB(N − j)
fAj + fB(N − j)
Πj→j = 1−Πj→j+1 −Πj→j−1 .
(S1)
The Moran process is a discrete-time Markov process, since the probabilities of states j after
one step only depend upon the present value of j. Let us take the limit of continuous time and
write the master equation P˙ = RAP giving the probability of being at state j at time t:
d
dt


P0
P1
P2
...
PN

 =


−Π0→1 Π1→0 0 · · · 0
Π0→1 −(Π1→0 +Π1→2) Π2→1 (0)
...
0 Π1→2 −(Π2→1 +Π2→3) . . . 0
... (0)
. . .
. . . ΠN→N−1
0 · · · 0 ΠN−1→N −ΠN→N−1




P0
P1
P2
...
PN

 .
(S2)
This Markov chain has two absorbing states, namely j = 0 and j = N , which correspond to the
fixation of B and A individuals, respectively. Once these states are reached, no more changes
can occur, in the absence of mutation. It follows that all the components of the first and the last
columns of RA equal to 0 (see Eq. S2), so RA is not invertible. In the following, we will denote
by R˜A the reduced transition rate matrix in which the rows and the columns corresponding to
the absorbing states (j = 0, j = N) are removed, and by R˜−1
A
its inverse. Let us note that RA is
a tridiagonal matrix, which allows for major simplifications of analytical calculations [20]. Note
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that in order to obtain the transition rate matrix associated to B individuals, one just needs to
apply the reversal j ↔ N − j. This corresponds to using the matrix RB = JRAJ where J is
the anti-identity matrix. For instance, in 2 dimensions, J =
(
0 1
1 0
)
.
2.2 General fixation probabilities and fixation times
Definitions. The fixation probability φAj0 represents the probability that A individuals finally
succeed and take over the population, starting from j = j0 individuals of type A. In particular,
φA0 = 0 and φ
A
N = 1. Similarly, φ
B
j0
is the fixation probability of the B individuals, still starting
from j = j0 individuals of type A.
Mean fixation times are the mean times to reach one of the absorbing states. The uncondi-
tional fixation time tj0 is the average time until fixation in either j = 0 or j = N , when starting
from a number j = j0 of A individuals. The conditional fixation time t
A
j0
corresponds to the
average time until fixation in j = N , when starting from j0, provided that type A fixes. Note
that in what follows, we will express the fixation times in numbers of steps of the Moran process.
Conversion to generations can then be performed by dividing the number of Moran steps by N .
In the following, we present a derivation of the fixation probabilities and of the fixation times
in the Moran process [20, 24] that uses the general formalism of mean first passage times [54].
Fixation probabilities. Assuming that at t = 0, the system is at state j = j0, let us focus
on the fixation probability φAj0 of the A type in the population. The stochastic process stops at
the time τ̂FP when j fixes, i.e. first reaches one of the absorbing states {j = 0, j = N}. Hence,
integrating over all values of τ̂FP , under the condition that fixation finally occurs in j = N ,
yields
φAj0 =
∫ ∞
0
p(τ̂FP ∈ [t, t+ dt] | j0 , j∞ = N) = ΠN−1→N
∫ ∞
0
PN−1(t)dt . (S3)
In the last expression, we have taken advantage of the fact that the only way to fix in j = N
between t and t+ dt is to be in state j = N − 1 at time t and then to transition from N − 1 to
N (see Eq. S2). We have thus introduced the probability PN−1(t) of being in state j = N − 1 at
time t, starting in state j = j0 at time 0. More generally, the probability Pi(t) can be considered.
Integrating the Master equation Eq. S2 to determine Pi(t), with the initial condition Pi(0) =
δi j0 , where δi j0 denotes the Kronecker delta, which is equal to 1 if i = j0 and 0 otherwise, yields
φAj0 = −ΠN−1→N (R˜−1A )N−1 j0 . (S4)
A similar reasoning gives the fixation probability φBj0 of the B type, still starting from j0
individuals of type A and N − j0 individuals of type B:
φBj0 = −Π1→0(R˜−1A )1 j0 . (S5)
These two probabilities satisfy φAj0 + φ
B
j0
= 1 since there are 2 absorbing states in the process.
Mean fixation times. Let us now focus on the mean fixation times, still assuming that at
t = 0, the system is at state j = j0. The probability that fixation in one of the absorbing states
{j = 0, j = N} occurs between t and t+ dt reads:
p(τ̂FP ∈ [t, t+ dt] | j0) =
N−1∑
i=1
Pi(t)−
N−1∑
i=1
Pi(t+ dt) = −
N−1∑
i=1
dPi
dt
dt , (S6)
where, as above, Pi(t) represents the probability of being in state i at time t starting in j0 at
time 0 (note that the initial condition j0 is omitted for brevity). Thus, the unconditional fixation
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time can be expressed as:
tj0 = E[τ̂FP | j0] =
∫ ∞
0
t p(τ̂FP ∈ [t, t+ dt] | j0) (S7)
= −
N−1∑
i=1
∫
∞
0
t
dPi
dt
dt =
N−1∑
i=1
∫
∞
0
Pi(t) dt . (S8)
Here, we used Eq. S6, where the sums run over all the states that are not absorbing (1 ≤ i ≤
N − 1). We also performed an integration by parts, and used [t Pi(t)]∞0 = 0 for 1 ≤ i ≤ N − 1,
which holds because the probability of reaching an absorbing state of the Markov chain tends
to 1 as t → ∞. Integrating the Master equation Eq. S2 to determine Pi(t), with the initial
condition Pi(0) = δi j0 , gives
tj0 = −
N−1∑
i=1
(R˜−1
A
)i j0 . (S9)
To express the conditional fixation time tAj0 of type A, starting from j0 A individuals, we
need to take into account the condition that fixation finally occurs in state j = N :
p(τ̂FP ∈ [t, t+ dt] | j0, j∞ = N) =
N−1∑
i=1
p(i | j0, j∞ = N)(t)−
N−1∑
i=1
p(i | j0, j∞ = N)(t+ dt) . (S10)
The Bayes relation gives:
p(j | j0, j∞ = N) =
φAj
φAj0
Pj . (S11)
By using the same method as for the unconditional fixation time, one obtains:
tAj0 = −
1
φAj0
N−1∑
i=1
φAi (R˜
−1
A
)i j0 . (S12)
Similarly, the conditional fixation time of the B type, starting from j0 A individuals, reads:
tBj0 = −
1
φBj0
N−1∑
i=1
φBN−i(R˜
−1
B
)i N−j0 . (S13)
It is straightforward to verify that Eqs. S9, S12 and S13 are linked by the relation:
tj0 = φ
B
j0t
B
j0 + φ
A
j0t
A
j0 . (S14)
Neutral drift. Let us first consider the case without selection fA = fB. In this case, the
Moran process can be seen as a non-biased random walk, since individuals of both types are
equally likely to be picked for reproduction and death. Fixation eventually happens due to
fluctuations. This process, called neutral drift [20] corresponds to diffusion in physics. The
transition rates of the system (S1) simplify as follows:

Πj→j+1 = Πj→j−1 =
j(N − j)
N2
Πj→j = 1− 2j(N − j)
N2
.
(S15)
Note that here, j can denote the number of A or B individuals indifferently. Indeed, the sym-
metry j ↔ N − j entails RA = RB = R, and the transition rate matrix is centrosymmetric, i.e.
R = JRJ. For consistency, we will continue to call j the number of A individuals.
The fixation probability φAj0 can be obtained from Eq. S4. It involves elements of the inverse
of the transition rate matrix. Solving R˜R˜−1 = I, where I is the identity matrix, gives
(R˜−1)N−1 i = − iN
N − 1 for 1 ≤ i ≤ N − 1 . (S16)
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Hence,
φAj0 =
j0
N
. (S17)
Taking advantage of the centrosymmetry of R (see above), a property which transfers to R˜ and
R˜−1, and entails (R˜−1)1 j0 = (R˜
−1)N−1N−j0 , we can apply Eq. S5, yielding
φBj0 =
N − j0
N
. (S18)
Note that φAj0 + φ
B
j0
= 1, as expected.
Let us now express the fixation times, focusing on the fate of a single mutant of type B,
which corresponds to j0 = N − 1. To compute the unconditional fixation time tN−1, we again
need elements of the inverse of the transition rate matrix (see Eq. S9), which are given by
(R˜−1)i N−1 = − N
N − i . (S19)
Using Eqs. S9 and S19, we obtain:
tN−1 = N
N−1∑
i=1
1
i
. (S20)
Similarly, using Eqs. S12, S17 and S19, we obtain the conditional fixation time of type A:
tAN−1 =
N2
N − 1
N∑
i=2
1
i
. (S21)
Finally, using Eqs. S13, S17 and S19, and making use of the centrosymmetry of R˜−1 (see above),
yields the conditional fixation time of type B:
tBN−1 = N(N − 1) . (S22)
Selection. Let us now study the more general case involving selection. For this, let us consider
two types A and B having different fitnesses fA and fB , and let us introduce γ = fA/fB. Note
that with selection, the transition rate matrices RA and RB = JRAJ are different. In order
to compute the fixation probability φAj0 , we need some elements of the inverse of the transition
rate matrix R˜−1
A
, which are given by:
(R˜−1
A
)N−1 i = − N
N − 1
1− γ−i
1− γ−N
(
N − 1 + γ−1) for 1 ≤ i ≤ N − 1 . (S23)
Then, using the previous result and Eq. S4, one obtains:
φAj0 =
1− γ−j0
1− γ−N , (S24)
and φAj0 + φ
B
j0
= 1 yields:
φBj0 =
1− γN−j0
1− γN . (S25)
Let us now turn to the fixation times. According to Eq. S9, we need to compute other
elements of the inverse of the transition rate matrix R˜−1
A
. Those satisfy:
(R˜−1
A
)i N−1 =
N
i(N − i)
1− γi
1− γN (i− iγ −N) for 1 ≤ i ≤ N − 1. (S26)
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Using Eqs. S9 and S26, the unconditional fixation time reads:
tN−1 =
N
1− γN
N−1∑
i=1
(N + iγ − i)(1 − γi)
i(N − i) . (S27)
To compute the conditional fixation time tAN−1, we substitute Eqs. S24 and S26 in Eq. S12,
obtaining:
tAN−1 =
N
(1− γN )(1 − γ1−N )
N−1∑
i=1
(N + iγ − i)(1 − γi)(1− γ−i)
i(N − i) . (S28)
A similar reasoning can be used to obtain the conditional fixation time tBN−1 starting from
Eq. S13. In order to express the required (R˜−1
B
)j 1, we combine the relation R˜B = JR˜AJ, which
implies R˜−1
B
= JR˜−1
A
J, together with Eq. S26, and obtain
(R˜−1
B
)i 1 =
N
i(N − i)
1− γN−i
1− γN (iγ − i−Nγ) for 1 ≤ i ≤ N − 1. (S29)
This finally yields
tBN−1 =
N
(1− γN )(1 − γ)
N−1∑
i=1
(N + iγ − i)(1− γi)(1− γN−i)
i(N − i) . (S30)
2.3 Fixation probabilities and fixation times used in the main text
Let us now make an explicit link between the general expressions obtained above and the fixation
probabilities and fixation times used in the main text.
Fixation probabilities. First, in the main text, pSR represents the probability that a single
resistant (R) mutant fixes without antimicrobial in a population of size N where all other
individuals are of type S. Without antimicrobial, fS = 1 and fR = 1− δ. Considering S as type
A and R as type B, we have γ = fS/fR = 1/(1 − δ), and our initial condition is j0 = N − 1.
Hence, Eq. S25 yields
pSR = φ
R
N−1 =
1− (1− δ)−1
1− (1− δ)−N . (S31)
In particular, in the effectively neutral case where δ ≪ 1 and Nδ ≪ 1, it yields
pSR ≈ −δ
1− e−N log(1−δ) ≈
−δ
1− eNδ ≈
1
N
, (S32)
i.e. we recover the result of the neutral case δ = 0 (see Eq. S17). Conversely, in the regime
where δ ≪ 1 and Nδ ≫ 1, Eq. S31 yields
pSR ≈ −δ
1− eNδ ≈ δe
−Nδ . (S33)
Second, pRC denotes the fixation probability of a single C individual in a population of size
N where all other individuals are of type R. Independently of antimicrobial presence, fR = 1− δ
and fC = 1. Considering R as type A and C as type B, we have γ = fR/fC = 1 − δ, and our
initial condition is j0 = N − 1. Hence, Eq. S25 yields
pRC = φ
C
N−1 =
δ
1− (1− δ)N . (S34)
In particular, in the effectively neutral case where δ ≪ 1 and Nδ ≪ 1, it yields
pRC =
δ
1− eN log(1−δ) ≈
δ
1− e−Nδ ≈
1
N
, (S35)
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i.e. we again recover the result of the neutral case δ = 0 (see Eq. S17). Conversely, in the
regime where δ ≪ 1 and Nδ ≫ 1, Eq. S34 yields
pRC ≈ δ
1− e−Nδ ≈ δ . (S36)
Finally, pSC denotes the fixation probability of a single C mutant in a population of S
individuals, without antimicrobial. In this case, fS = fC = 1, so we are in the neutral case, and
Eq. S17 yields pSC = 1/N .
Fixation times. First, τdR denotes the average time it takes for the lineage of a single R
mutant to disappear in the absence of antimicrobial. Hence, it is equal to the fixation time of
the S type in a population that initially contains N − 1 individuals of type S and 1 individual
of type R. Considering S as type A and R as type B, we have γ = fS/fR = 1/(1 − δ) without
antimicrobial, and our initial condition is j0 = N − 1, so τdR is equal to tSN−1/N (see Eq. S28).
Recall that tSN−1 needs to be divided by the population size N because we expressed it in
numbers of steps of the Moran process, while τdR has to be expressed in numbers of generations.
While the general formula Eq. S28 is rather complex, in the neutral case δ = 0, it reduces to
the much simpler expression in Eq. S21, which yields τdR ≈ logN for N ≫ 1. For δ > 0, τdR
is shorter than in the neutral case, because the R mutants are out-competed by S individuals.
Note that a good approximation to the exact formula in Eq. S28 can be obtained within the
diffusion approach [20] (see the Fokker-Planck equation below).
Second, τ fR denotes the average time needed for the R mutants take over with antimicrobial,
starting from one R mutant and N − 1 S individuals. Considering S as type A and R as type
B, we have γ = fS/fR = 0 with antimicrobial, and our initial condition is j0 = N − 1. Then τ fR
is equal to tRN−1/N (see Eq. S30), with γ = 0. Using Eq. S30, we obtain
τ fR =
N−1∑
i=1
1
i
, (S37)
which entails τ fR ≈ logN for N ≫ 1.
Finally, τ fC denotes the average time needed for the C mutants to take over, starting from
one C mutant and N − 1 R individuals. Considering R as type A and C as type B, we have
γ = fR/fC = 1 − δ, independent whether antimicrobial is present or absent, and our initial
condition is j0 = N − 1. Hence, τ fC is given by tCN−1/N (see Eq. S30). In the neutral case δ = 0,
tCN−1 reduces to Eq. S22, and thus τ
f
C ≈ N for N ≫ 1. For δ > 0, it is shorter, as selection
favors the fixation of C, and again a good approximation to the exact formula in Eq. S30 can
be obtained within the diffusion approach [20] (see the Fokker-Planck equation below).
3 Large populations: deterministic limit
If stochastic effects are neglected, the dynamics of a microbial population can be described
by coupled differential equations on the numbers of individuals of each genotype [20]. This
deterministic approach is appropriate if the number N of competing microorganisms satisfies
Nµ1 ≫ 1 [34]. Here, we derive and study the deterministic limit of the complete stochastic
model studied in the main text.
3.1 From the stochastic model to the deterministic limit
Here, we present a full derivation of the deterministic limit of the stochastic model based on
the Moran process (see above). This derivation closely follows those of Refs. [23, 24] and is
presented here for the sake of pedagogy and completeness. Starting from the Master equation
of our stochastic model, we obtain a Fokker-Planck equation, corresponding to the diffusion
approximation [20], and then a deterministic differential equation, in the limits of increasingly
large population sizes.
22
Let us first recall the Master equation corresponding to the Moran process, where j denotes
the number of A individuals and N − j the number of B individuals, as above:
dPj(t)
dt
= Pj−1(t)Πj−1→j + Pj+1(t)Πj+1→j − Pj(t) (Πj→j−1 +Πj→j+1) . (S38)
The notations in Eq. S38 are the same as in the previous section, and time is expressed in
number of steps of the Moran process. Let us now introduce the reduced variables x = j/N ,
τ = t/N , as well as ρ(x, τ) = NPj(t). Then, since one step of the Moran process occurs each
time unit, Eq. S38 can be rewritten as:
ρ(x, τ + 1/N)− ρ(x, τ) = ρ(x− 1/N, τ)Π+(x− 1/N) + ρ(x+ 1/N, τ)Π−(x+ 1/N)
− ρ(x, τ) (Π−(x) + Π+(x)) , (S39)
with
Π−(x) = Πj→j−1 =
fBx(1− x)
fA x+ fB (1− x) and Π
+(x) = Πj→j+1 =
fAx(1− x)
fA x+ fB (1− x) . (S40)
Diffusion approximation. For N ≫ 1, considering that jumps are small at each step of the
Moran process, i.e. 1/N ≪ x and 1/N ≪ τ , the probability density ρ(x, τ) and the transition
probabilities Π±(x) can be expanded in a Taylor series around x and τ . This expansion, known
as a Kramers-Moyal expansion [55], yields, to first order in 1/N :
∂ρ(x, τ)
∂τ
= − ∂
∂x
[ρ(x, τ)a(x)] +
1
2
∂2
∂x2
[
ρ(x, τ)b2(x)
]
(S41)
with
a(x) = Π+(x)−Π−(x) and b2(x) = Π
+(x) + Π−(x)
N
. (S42)
Eq. S41 is known as a diffusion equation, or a Fokker-Planck equation, or a Kolmogorov forward
equation [55], and a(x) corresponds to the selection term (known as the drift term in physics),
while b2(x) corresponds to the genetic drift term (known as the diffusion term in physics).
Deterministic limit. In the limit N →∞, retaining only the zeroth-order terms in 1/N , Eq.
S41 reduces to:
∂ρ(x, τ)
∂τ
= − ∂
∂x
[ρ(x, τ)a(x)] . (S43)
Let us focus on the average value of x, denoted by 〈x〉. Using Eq. S41 yields
d〈x〉
dτ
=
∫ 1
0
∂ρ(x, τ)
∂τ
x dx = −
∫ 1
0
∂
∂x
[ρ(x, τ) a(x)] dx (S44)
= − [x ρ(x, τ) a(x)]10 +
∫ 1
0
ρ(x, τ) a(x) dx (S45)
= 〈a(x)〉 (S46)
The first term of right hand side of Eq. S45 vanishes because a(0) = a(1) = 0. In the limit
N → ∞, the distribution of x is very peaked around its mean, so 〈x〉 ≈ x and 〈a(x)〉 ≈ a(x),
yielding:
dx
dτ
= x(1− x)∆f
f¯
, (S47)
where ∆f = fA − fB denotes the difference of the fitnesses of the two types, while f¯ = fA x+
fB (1− x) is the average fitness in the population. Eq. S47 is an ordinary differential equation
known as the adjusted replicator equation [23]. Recall that τ corresponds to the number t of
steps of the Moran process divided by the total number N of individuals in the population.
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Hence, τ is the time in numbers of generations used in the main text, and Eq. S47 is the proper
deterministic limit for our stochastic process.
Note that in the framework of the Moran process, fitnesses are only relative. If one wanted
to account for absolute fitness effects, so that a whole population reproduces faster if its average
fitness is higher, one would need to include an additional rescaling of time τ ′ = τ/f¯ . Note that
if f¯ is constant, this rescaling yields a standard replicator equation:
dx
dτ ′
= x(1− x)∆f . (S48)
3.2 Deterministic description of the evolution of antimicrobial resistance
System of ordinary differential equations. Let us now come back to our model of the
evolution of antimicrobial resistance, with three types of microorganisms (see Fig. 1A). In the
limit of large populations, the complete stochastic model described in the main text will converge
to a deterministic system of ordinary differential equations, as demonstrated above. Generalizing
Eq. S48, by considering three types of individuals and taking into account mutations, yields a
system of replicator-mutator equations [24]:

s˙ = fS(1− µ1)s − fs
r˙ = fR(1− µ2)r + fS µ1 s− f r
s+ r + c = 1 ,
(S49)
where s, r and c are the population fractions of S (sensitive), R (resistant) and C (resistant-
compensated) microorganisms, respectively, while fS, fR and fC denote their fitnesses, f =
fS s+fR r+fC c denotes the average fitness in the population, and dots denote time derivatives.
To illustrate that Eq. S49 generalizes Eq. S48, consider the case where c = 0 and µ1 = 0: the
first equation of Eq. S48 then yields s˙ = fSs − [fSs + fR(1 − s)]s = s(1 − s)(fS − fR). As
demonstrated above, the deterministic limit of our stochastic model yields adjusted replicator
equations (see Eq. S47). For the sake of simplicity, the present analytical discussion focuses on
standard replicator equations (see Eq. S48).
The system of equations Eq. S49 only concerns population fractions, and constitutes the
large-population limit N → ∞ of our stochastic model at constant N . It is mathematically
convenient to note that the same equations are obtained in the case of a population in which
microorganisms have an exponential growth. This model, which enables us to recover the system
S49, is governed by the following system of linear differential equations:

N˙S = fS(1− µ1)NS
N˙R = fR(1− µ2)NR + fS µ1NS
N˙C = fCNC + fR µ2NR ,
(S50)
where NS, NR and NC are the numbers of sensitive, resistant and resistant-compensated mi-
croorganisms, respectively. It is straightforward to show that the population fractions obtained
from this exponential growth model satisfy Eq. S49: hence, this simple deterministic model
allows one to understand the evolution of large microbial populations described by the Moran
model (even though the total population is constant in the Moran model).
Analytical resolution. Being linear, the system in Eq. S50 is straightforward to solve ana-
lytically:
SR
C

 =


0 0 1
0 1 fS µ1fS(1−µ1)−fR(1−µ2)
1 fR µ2fR(1−µ2)−fC
fS µ1 fR µ2
(fS(1−µ1)−fR(1−µ2))(fS(1−µ1)−fC)



 β1 efC tβ2 efR(1−µ2)t
β3 e
fS(1−µ1)t

 (S51)
where β1, β2 and β3 can be expressed from the initial conditions S(0), R(0) and C(0). The
fractions s, r and c can then be obtained from this solution, e.g. through s = S/(S +R+C).
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Limiting regimes and characteristic timescales. As in the main text, we are going to
focus on the case where the population initially only comprises sensitive microorganisms, i.e.
s(0) = 1. In the case of periodic alternations of absence and presence of antimicrobial, a small
fraction of R microorganisms will appear within the first half-period without antimicrobial.
The subsequent evolution of the population composition can be separated into three successive
regimes. In the first one, it suffices to consider S and R microorganisms, as the fraction of
C is negligible, because the appearance of C requires an additional mutation. The second
regime is more complex, and involves all three types of microorganisms, as the growth of C
microorganisms makes the fractions of S and R microorganisms decrease. Then, provided that
antimicrobial has been present for a sufficient time, the fraction of S microorganisms becomes
negligible, because they cannot divide with antimicrobial. Hence, the third regime only involves
R and C microorganisms, and does not depend on the presence or absence of antimicrobial,
because the fitnesses of R and C are unaffected. Here, we determine analytically the main
timescales involved in these first and third regimes.
First regime: S vs. R. Let us consider the first regime where there are almost only S and R
microorganisms. We are interested in the population fractions s(t) and r(t), with s(t)+r(t) ≈ 1.
Eq. S49 then gives:
s˙ = s (∆f1 − s∆f2) , (S52)
where we have defined ∆f1 = fS(1 − µ1) − fR and ∆f2 = fS − fR. Note that we expect
∆f1 ≈ ∆f2, since biologically relevant values generally satisfy µ1 ≪ 1 and µ1 ≪ δ. The solution
of Eq. S52 reads
s(t) =
s0 e
∆f1t
1− s0∆f2∆f1 + s0
∆f2
∆f1
e∆f1t
, (S53)
where s0 is the fraction of S microorganisms at the beginning of the first regime (taken as t = 0
here). In the presence of antimicrobial (fS = 0), the previous expression can be simplified, using
∆f1 = ∆f2 = −(1 − δ). This allows us to identify the characteristic time τ1 of the decay of s,
as R microorganisms take over:
τ1 =
−1
∆f1
=
1
1− δ . (S54)
The duration t1 of the first regime in the presence of antimicrobial is governed by τ1. More
precisely, Eq. S53 yields:
t1 =
1
1− δ log
(
s0 (1− s1)
s1 (1− s0)
)
, (S55)
where s1 is the fraction of S microorganisms at the end of the first regime, at which point
the fraction of C microorganisms is no longer negligible.
Third regime: R vs. C. Let us now turn to the third regime, assuming that antimicrobial
has been present for a long enough time to allow S microorganisms to become a small minority.
Eq. S49 then gives:
r˙ = r (∆f3 − r∆f4) , (S56)
with ∆f3 = fR(1 − µ2) − fC = −δ(1 − µ2) − µ2 and ∆f4 = fR − fC = −δ, independently of
whether antimicrobial is present or not. Again, we generally expect ∆f3 ≈ ∆f4. The solution
of Eq. S56 reads
r(t) =
r2 (1− µ2 + µ2/δ) e−(δ(1−µ2)+µ2)t
1− µ2 + µ2/δ − r2 + r2 e−(δ(1−µ2)+µ2)t
≈
µ2≪1
µ2≪δ
r2 e
−δt
1− r2 + r2 e−δt , (S57)
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where r2 is the fraction of R microorganisms at the beginning of the third regime (taken as t = 0
here). Hence, the characteristic time τ3 of the decay of r reads:
τ3 =
1
µ2 + δ(1 − µ2) ≈µ2≪1
µ2≪δ
1
δ
. (S58)
The duration t3 of the third regime in the presence of antimicrobial is governed by τ3. More
precisely, Eq. S57 yields:
t3 ≈
µ2≪1
µ2≪δ
1
δ
log
(
r2 (1− r3)
r3 (1− r2)
)
. (S59)
where r3 is the fraction of R microorganisms at the end of this regime, when C has become
dominant in the population.
Note that the timescales obtained here are governed by selection (through the relevant fitness
differences δ and 1− δ). This stands in contrast with the results from our stochastic model (see
main text) where mutation rates are crucial, especially through the waiting time before resistant
mutants appear. In the deterministic description considered here, small fractions of resistant
mutants appear right away, so this consideration is irrelevant. However, mutation rates come
into play in the durations of the different regimes within the deterministic model, through the
fractions of each type of microorganisms at the beginning and at the end of each regime, but
with a weak logarithmic dependence (see Eqs. S55-S59).
3.3 Comparison of stochastic and deterministic results
As in the main text, we now focus on the impact of a periodic presence of antimicrobial on
the time it takes for a population to fully evolve resistance. For large microbial populations
satisfying N ≫ 1/µ1, we wish to check that the system of differential equations in Eq. S49
recovers the results obtained with our stochastic model. To this end, we solve the system in
Eq. S49 numerically in the case of a periodic presence of antimicrobial. Note that complete
fixation of a genotype does not happen in the deterministic model. Conversely, in the stochastic
model, for a population of size N , the fixation of C corresponds to the discrete Moran step where
the fraction c jumps from 1 − 1/N to 1. Hence, for our comparison between the deterministic
results and the stochastic ones obtained for N microorganisms, we consider that C effectively
fixes in the deterministic model when the fraction c reaches 1− 1/N . In addition, for exactness,
we use a numerical resolution of the system in Eq. S49 where time is rescaled through t→ t/f¯ .
Indeed, the proper deterministic limit of our stochastic model corresponds to modified replicator
equations, such as Eq. S47 (see above).
Fig. S2 shows that the deterministic model yields results very close to those obtained through
the stochastic model, in the case of large population sizes N ≥ 1/µ1. We recover the regimes
described in the main text, with a plateau for short periods, and a linear dependence on T for
larger ones. Moreover, the relative error made by using the deterministic model instead of the
stochastic one is less than ∼20% (resp. ∼10%) for all data points with N = 105 (resp. N = 106)
in Fig. S2.
Let us now present an analytical approximation for tfC, based on the different timescales
computed previously. As the population is initially only composed of S microorganisms, they
will remain dominant during the first half-period without antimicrobial, since they are fitter
than R mutants (and we assume that T/2 is not large enough to extend to the point where C
starts being important, which would then correspond to the valley crossing case). Afterwards, R
microorganisms start growing fast during the second half-period. Note that in the deterministic
case, there is always a nonzero fraction of resistant microorganisms at the end of the first half-
period without antimicrobial, contrary to the stochastic case studied in the main text. Hence, we
compute the fraction s0 = s(T/2) of S microorganisms at the end of the first half period, by using
results for the above-described first regime without antimicrobials. This fraction s0 = s(T/2) is
then taken as the initial condition of the first regime with antimicrobial. Then, for simplicity,
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Figure S2: Large populations: stochastic model vs. deterministic model. The total
time tfC of full resistance evolution is plotted versus the period T of alternations of absence and
presence of antimicrobial, in the case of symmetric alternations. Results from simulations of the
stochastic model (see Fig. 3A), numerical resolution of the deterministic model, and an analytical
approximation of the deterministic solution (Eqs. S60-S61), are represented for N = 105 (A)
and N = 106 (B). Parameter values: µ1 = 10
−5, µ2 = 10
−3, and δ = 0.1.
we assume that s decays until it reaches s1 ≈ 0.1 (so r1 ≈ 0.9), while remaining in the first
regime described above, in the presence of antimicrobial. We then assume the duration of the
second regime is negligible, and consider that the third regime process starts right away, with
a fraction r2 ≈ 0.9. As explained above, we consider that the third regime ends upon effective
fixation of C, i.e. when c reaches 1 − 1/N , which implies r3 = 1/N . Using Eqs. S55 and S59,
we obtain:
tfC ≈
T
2
+
1
1− δ log
(
9 s(T/2)
1− s(T/2)
)
+
1
δ
log (9(N − 1)) , (S60)
where s(T/2) is obtained by using Eq. S53 in the absence of antimicrobial:
s(T/2) =
e(µ2+δ(1−µ2)−µ1)T/2
1− µ2+δ(1−µ2)µ2+δ(1−µ2)−µ1
(
1− e(µ2+δ(1−µ2)−µ1)T/2) . (S61)
Eqs. S60-S61 yield good approximations of the analytical results obtained by numerical
resolution of Eq. S49, as can be seen on Fig. S2. More precisely, the relative error made by
using this approximation instead of the full numerical resolution is less than ∼ 13% for all
parameters in Fig. S2.
For T ≫ 2/δ, Eq. S61 reduces to s(T/2) ≈ 1−µ1/[µ2+δ(1−µ2)] ≈ 1−µ1/δ, so only the first
term in Eq. S60 then depends on T . Hence, this term becomes dominant for large T , yielding
tfC ≈ T/2 in this limit. This asymptotic behavior is again consistent with our predictions from
the stochastic model (see main text). The horizontal purple solid line at large T in Fig. 3A, and
the horizontal solid lines at large N in Fig. 3B, both correspond to tfC ≈ T/2, showing excellent
agreement with our stochastic simulations as well.
Conversely, for small periods, the first term of Eq. S60 can be neglected, so the dependence
on T of tfC is weaker (Eq. S61 reduces to s(T/2) ≈ 1−µ1T/2 for T ≪ 2/δ, so a weak logarithmic
dependence on T remains, due to the second term of Eq. S60). It is interesting to note that the
third term of tfC in Eq. S60 also increases logarithmically with N . This stands in contrast with
the case of smaller populations, where our stochastic study showed that tfC essentially decreases
linearly with N (see main text). This change of behavior as N increases can be seen on Fig. 3A
in the regime of small T (in particular, for large N , the purple data points corresponding to
N = 106 are then slightly higher than the blue ones corresponding to N = 105; see also Fig. S2,
where the y-axis range and scale are the same on panels A and B).
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4 Comparison to spontaneous fitness valley crossing
4.1 No antimicrobial: Crossing of a symmetric fitness valley
Let us compare the alternation-driven evolution of resistance to what would happen in the
absence of alternations of phases of absence and presence of antimicrobial. If a population
composed only of S (sensitive) microorganisms is subjected to a continuous presence of antimi-
crobial, it will not evolve resistance, because divisions are blocked (see Fig. 1A). Conversely,
a population of S microorganisms that is never subjected to antimicrobial can spontaneously
evolve resistance. In our model, this will eventually happen. This process is difficult and slow,
because of the initial fitness cost of resistance: it requires crossing a fitness valley (see Fig. 1A).
Fitness valley crossing has been studied in detail [22, 42, 56–58], but usually in the case where
the final mutant has a higher fitness than the initial organism. In the evolution of antimicro-
bial resistance, compensatory mutations generally yield microorganisms with antimicrobial-free
fitnesses that are similar to, but not higher than those of sensitive microorganisms [3, 4, 6].
Hence, we here extend the known results for fitness valley crossing by constant-size homoge-
neous asexual populations [22] to “symmetric” fitness valleys, where the final genotype has no
selective advantage compared to the initial one. Briefly, the main difference with Ref. [22] is
that the probability of establishment of the second mutant (C) in a population with a majority
of non-mutants (S) is 1/N instead of being given by the selective advantage s of the second
mutant. This probability plays an important role in the tunneling case.
There are two different ways of crossing a fitness valley. In sequential fixation, the first
deleterious mutant fixes in the population, and then the second mutant fixes. In tunneling [56],
the first mutant never fixes in the population, but a lineage of second mutants arises from a
minority of first mutants, and fixes. For a given valley, characterized by δ (see Fig. 1A), popu-
lation size N determines which mechanism dominates. Sequential fixation requires the fixation
of a deleterious mutant through genetic drift, and dominates for small N , when stochasticity is
important. Tunneling dominates above a certain N [22, 57]. Let us study these two mechanisms
in the regime of rare mutations Nµ1 ≪ 1 where stochasticity is crucial.
In sequential fixation, the average time τSF to cross a valley is the sum of those of each
step involved [22]. Hence τSF = 1/(Nµ1pSR) + 1/(Nµ2pRC), where pSR (resp. pRC) is the
fixation probability of a single R (resp. C) individual in a population of size N where all other
individuals are of type S (resp. R). Fixation probabilities are known in the Moran process (see
Supplementary Material, Section 2). In particular, if Nδ ≪ 1 then pSR ≈ pRC ≈ 1/N for our
symmetric valley, so τSF ≈ 1/µ1 + 1/µ2 (≈ 1/µ1 if µ1 ≪ µ2), while if δ ≪ 1 and Nδ ≫ 1 then
pSR ≈ δe−Nδ and pRC ≈ δ ≫ pSR, so τSF ≈ eNδ/(Nµ1δ).
In tunneling, the key timescale is that of the appearance of a successful first (R) mutant,
i.e. a first mutant whose lineage will give rise to a second (C) mutant that will fix in the
population [22]. Neglecting subsequent second mutation appearance and fixation times, the
average tunneling time reads τT ≈ 1/(Nµ1p1), where p1 is the probability that a first mutant is
successful [22]. Upon each division of a first mutant, the probability of giving rise to a second
mutant that will fix is p = µ2pSC, where pSC is the fixation probability of a single C mutant in a
population of S individuals. For our symmetric valley, pSC = 1/N , so p = µ2/N . In the neutral
case δ = 0, Ref. [22] demonstrated that the first-mutant lineages that survive for at least ∼1/√p
generations, and reach a size ∼ 1/√p, are very likely to be successful, and fully determine the
rate at which successful first mutants are produced. Since the lineage of each new first mutant
has a probability ∼√p of surviving for at least ∼ 1/√p generations [22], the probability that
a first mutant is successful is p1 ∼√p ∼
√
µ2/N . If δ > 0, a first mutant remains effectively
neutral if its lineage size is smaller than 1/δ [22]. Hence, if δ <
√
µ2/N , p1 ∼
√
µ2/N still
holds. (This requires Nµ2 ≫ 1, otherwise the first mutant fixes before its lineage reaches a size√
N/µ2.) Finally, if δ >
√
µ2/N , the lineage of a first mutant will reach a size at most ∼ 1/δ,
with a probability ∼δ and a lifetime ∼1/δ [22], yielding p1 ∼µ2/(Nδ).
Given the substantial cost of resistance mutations (δ ∼ 0.1 [4, 6]) and the low compensatory
mutation rates (in bacteria µ2 ∼ 10−8 [4]), let us henceforth focus on the case where δ >
√
µ2/N
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(which is appropriate for all N ≥ 1 with the values mentioned). Then τT ≈ 1/(Nµ1p1) ≈
δ/(µ1µ2), and two extreme cases can be distinguished:
(A) Nδ ≪ 1 (effectively neutral regime): Then, τSF ≈ 1/µ1 (for µ1 ≪ µ2) and τT ≈ δ/(µ1µ2).
Given the orders of magnitude above, generally δ > µ2 in resistance evolution. Hence, sequential
fixation is fastest, and the valley crossing time τV reads:
τV = τSF ≈ 1
µ1
. (S62)
(B) δ ≪ 1 and Nδ ≫ 1: Then,
τV = min (τSF, τT) ≈ min
(
eNδ
Nµ1δ
,
δ
µ1µ2
)
. (S63)
The transition from sequential fixation to tunneling [22] occurs when Nδe−Nδ = µ2/δ.
We have focused on the rare mutation regime Nµ1 ≪ 1. If mutations are more frequent, the
first successful lineage of R mutants that appears may not be the one that eventually fixes, so
the valley-crossing time becomes shorter [22].
In Fig. 3B, the black simulation data points were obtained without any antimicrobial. The
population then evolves resistance by valley crossing. The black curves correspond to our ana-
lytical predictions in Eq. S62 for N ≪ 1/δ and in Eq. S63 for N ≫ 1/δ. In the latter regime,
the transition from sequential fixation to tunneling occurs at N ≈ 65 for the parameters of
Fig. 3B. The agreement between simulation results and analytical predictions is excellent, with
no adjustable parameter.
4.2 Alternation-driven process vs. valley-crossing process
Now that we have studied the spontaneous crossing of a symmetric fitness valley without any
antimicrobial, let us come back to our periodic alternations of phases of absence and presence of
antimicrobial. Resistance can then evolve by two distinct mechanisms, namely the alternation-
driven process and the spontaneous valley-crossing process. It is important to compare the
associated timescales, in order to assess which process will happen faster and dominate. This
will shed light on the acceleration of resistance evolution by the alternations. For generality, we
consider asymmetric alternations.
With alternations, spontaneous valley crossing can still happen, but new R lineages cannot
appear with antimicrobial, because S individuals cannot divide (see Fig. 1A). Since the appear-
ance of a successful R mutant is usually the longest step of valley crossing (see above), the
average valley crossing time τ ′V with alternations will be longer by a factor T/T1 than that with-
out antimicrobial (τV), if more than one antimicrobial-free phase is needed to cross the valley,
i.e. if T1 ≪ τV. Eqs. S62 and S63 then yield
τ ′V ≈
T
T1µ1
for Nδ ≪ 1 , (S64)
τ ′V ≈
T
T1
min
(
eNδ
Nµ1δ
,
δ
µ1µ2
)
for δ ≪ 1 and Nδ ≫ 1 . (S65)
Conversely, if T1 ≫ τV, valley crossing generally happens within the first antimicrobial-free
phase. Hence, the average valley crossing time τV is given by Eqs. S62 and S63. (Recall that
the process is assumed to begin with an antimicrobial-free phase.)
We can now compare the timescales of the valley-crossing process to those of the alternation-
driven process. For simplicity, let us assume that the dominant timescale in the latter process is
the time taR it takes to first observe an R organism in the presence of antimicrobial, i.e. t
f
C ≈ taR
(see Eq. 2). This is the case in a large and relevant range of parameters, especially if µ1 ≪ µ2, as
discussed above. Note also that the final step of fixation of the successful C lineage, which can
become long in large populations (up to ∼N in the neutral case, see Supplementary Material,
Section 2), is the same in the alternation-driven process and in the valley-crossing process, so it
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does not enter the comparison. The expression of taR in Eq. 3 should thus be compared to the
valley crossing time. If T1 ≫ τV, valley crossing happens before any alternation, and is thus the
relevant process, with time τV given by Eqs. S62 and S63. Let us now conduct our comparison
of taR and τ
′
V for T1 ≪ τV, where Eqs. S64 and S65 hold.
(A) If T1 ≪ τdR (recall that τdR is the average lifetime of an R lineage without antimicrobial,
before it goes extinct): The alternation-driven process, with timescale taR = T/(Nµ1T1) (see
Eq. 3), dominates. Indeed, if Nδ ≪ 1, τ ′V is given by Eq. S64, so for all N > 1, taR < τ ′V.
And if Nδ ≫ 1 and δ ≪ 1, Eq. S65 yields taR/τ ′V ≈ δe−Nδ ≪ 1 in the sequential fixation
regime, and taR/τ
′
V ≈ µ2/(Nδ) ≪ 1 in the tunneling regime. Hence, if T1 ≪ τdR, the alternation-
driven process dominates. Thus, alternations of absence and presence of antimicrobial strongly
accelerate resistance evolution. For instance, in Fig. 3A, for N = 100 and T/2 ≪ τdR, the
alternation-driven process takes taR = 2/(Nµ1) = 2 × 103 generations, while valley crossing
takes τV = δ/(µ1µ2) = 10
7 generations without antimicrobial: alternations yield a speedup of
4 orders of magnitude. The speedup is even stronger for larger populations. Conversely, for
T1 ≪ T2, while the alternation-driven process is shorter than the valley-crossing process in the
presence of alternations, it can nevertheless be longer than the valley-crossing process in the
absence of antimicrobial. In this case, the drug actually slows down the evolution of resistance.
When T1 ≪ T2 and T1 ≪ τdR, in the tunneling regime, provided that 1/N ≪ δ ≪ 2
√
µ2/N ,
valley crossing takes δ/(µ1µ2) in the absence of antimicrobial (see Eq. S63), and T2δ/(T1µ1µ2)
in the presence of alternations satisfying T1 ≪ T2 (see Eq. S65). Meanwhile, the switch-driven
process takes T2/(T1Nµ1) (see above). Hence, if T2 ≫ T1Nδ/µ2, the alternation-driven process
dominates, but it is slower than the valley-crossing process in the absence of antimicrobial: the
drug then slows down resistance evolution. This effect can be seen on Fig. 4 for T1 ≪ T2 and
T1 ≪ τdR.
(B) If T1 ≫ τdR: Then taR = T/(Nµ1τdR) (see Eq. 3). If Nδ ≪ 1, valley crossing by sequential
fixation is the dominant process. Indeed, Eq. S64 yields taR/τ
′
V ≈ T1/τdR ≫ 1. If Nδ ≫ 1 and
δ ≪ 1, Eq. S65 yields taR/τ ′V ≈ δe−NδT1/τdR in the sequential fixation regime, and taR/τ ′V ≈
µ2T1/(Nδτ
d
R) in the tunneling regime. A transition from the alternation-driven process to valley
crossing occurs when these ratios reach 1. Qualitatively, if N is large enough and/or if T1 is
short enough, the alternation-driven process dominates.
For example, in Fig. 4A, parameters are such that the dominant mechanism of valley crossing
is tunneling, so taR/τ
′
V reaches 1 for T1 = Nδτ
d
R/µ2 ≈ 2.6 × 105 generations. This transition to
the valley-crossing plateau is indeed observed for the curves with large enough T2. (Recall that
if T2 ≪ τ fR, extinction events occur when T1 ≫ τdR, see Fig. S3B.) The black horizontal lines
in Figs. 4A and 4B correspond to our analytical prediction in Eq. S65, giving τ ′V ≈ δ/(µ1µ2)
if T1 ≫ max(T2, τdR). Similarly, in Fig. 3A, horizontal solid lines at large T correspond to the
valley crossing times in Eqs. S64 or S65, depending on N . In Fig. 3B, in the regime of small
N and large T , resistance evolution is achieved by tunneling-type valley crossing, yielding a
plateau in the neutral regime N ≪ 1/δ (see Eq. S64, plotted as a horizontal purple line) and an
exponential increase for intermediate N (see Eq. S65). For larger N , we observe a T -dependent
transition to the alternation-driven process, which can be fully understood using the ratio taR/τ
′
V
(see above).
5 Detailed analysis of asymmetric alternations
5.1 Particular regimes
Here, we examine whether R mutants will fix during a single phase with antimicrobial, of
duration T2. The fixation time of the lineage of an R mutant in the presence of antimicrobial
is τ fR ≈ logN for N ≫ 1 [20] (see above). If T2 ≫ τ fR, fixation will happen within T2. In the
opposite case, the fixation of R is not likely to occur within a single phase with antimicrobial.
Two situations exist in this case (see Fig. S3).
(A) If T2 ≪ τ fR and T1 ≪ τdR (Fig. S3A): The R lineage will drift for multiple periods, but
its extinction is unlikely, as for symmetric alternations. This effect can induce a slight increase
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Figure S3: Particular regimes. The number of R individuals in the population is plotted
versus time under alternations of phases without (white) and with antimicrobial (gray). Data
extracted from simulation runs. (A) T2 ≪ τ fR and T1 ≪ τdR: the R lineage drifts for multiple
periods. Parameters: N = 103, T1 = 10
−1, T2 = 10
−2 . (B) T2 ≪ τ fR and T1 ≫ τdR: the R
lineage goes extinct. Parameters: N = 102, T1 = 10
2, T2 = 1. In both (A) and (B), µ1 = 10
−5,
µ2 = 10
−3 and δ = 0.1.
of the total time of resistance evolution, which is usually negligible.
(B) If T2 ≪ τ fR and T1 ≫ τdR (Fig. S3B): The R lineage is likely to go extinct even after it
has started growing in the presence of antimicrobial. This typically implies T1 ≫ T2, since τ fR ≈
logN and τdR . logN for N ≫ 1 (see above). Hence, this case is specific to (very) asymmetric
alternations. Spontaneous valley crossing then becomes the fastest process of resistance evolution
(see Supplementary Material, Section 4).
5.2 Varying T2 at fixed T1
In the main text, we present a detailed analysis of what happens when T1 is varied at fixed T2
(see Fig. 4A). Here, we present a similar analysis if T2 is varied at fixed T1. Fig. 4B shows the
corresponding simulation results, together with our analytical predictions from Eqs. 2 and 3. In
particular, a minimum is observed in Fig. 4B when varying T2 for T1 ≫ τdR:
• When T2 ≪ τdR ≪ T1, valley crossing dominates.
• When τdR ≪ T2 ≪ T1, Eq. 3 gives taR = T/(Nµ1τdR) ≈ T1/(Nµ1τdR), which is independent
from T2.
• As T2 is further increased, taR = T/(Nµ1τdR) increases, becoming proportional to T2 when
T2 ≫ T1.
Hence, the minimum of taR is T1/(Nµ1τ
d
R) and is attained for τ
d
R ≪ T2 ≪ T1. In the opposite
case where T1 ≪ τdR, Eq. 3 still gives taR = T/(Nµ1T1). Thus, taR reaches a plateau taR = 1/(Nµ1)
for T2 ≪ T1 ≪ τdR, which means that the first R mutant yields the full evolution of resistance
(as seen above). Then, taR becomes proportional to T2 for T2 ≫ T1. Note that valley crossing is
always slower than the alternation-driven process when T1 ≪ τdR (see above), so no plateau is
expected at large T2 in this case.
6 Robustness of the binary antimicrobial action model
Throughout our study, we have modeled the action of the antimicrobial in a binary way: below
the MIC (“absence of antimicrobial”), growth is not affected, while above it (“presence of an-
timicrobial”), sensitive microorganisms cannot grow at all (see Model section in the main text).
The relationship between antimicrobial concentration and microorganism fitness is termed the
pharmacodynamics of the antimicrobial [16, 49]. Our binary approximation is motivated by the
usual steepness of pharmacodynamic curves around the MIC [16]. However, this steepness is
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not infinite, and it is different for each antimicrobial. Here, we investigate the robustness of our
binary model.
If one goes beyond the binary model and accounts for the smoothness of the pharmacody-
namic curve, one additional factor enters the determination of the time dependence of fitness. It
is the time dependence of the antimicrobial concentration, typically in a treated patient, which
is known as pharmacokinetics [16, 49]. In fact, the time dependence of the fitness of sensitive mi-
croorganisms will be determined by a combination of pharmacodynamics and pharmacokinetics.
Experimental pharmacodynamic curves are well-fitted by Hill functions, and pharmacokinetic
curves are often modeled by exponential decays of drug concentration after intake [16]. The
fitness versus time curve upon periodic antimicrobial intake will be a smooth periodic function
resulting from the mathematical function composition of these two empirical relationships. The
main feature of this curve will be how smooth or steep it is, which can be characterized by its
rise time, i.e. the time it takes to rise from a value of fS close to 0 to one close to 1. Recall that
the fitness fS of sensitive microorganisms ranges between 0 at very high antimicrobial concen-
trations and 1 without antimicrobial. In practice, we chose to define the rise time as the time
taken to rise from fS = 0.1 to fS = 0.9.
Thus motivated, we consider a smooth and periodic fitness versus time relationship fS(t)
(see Fig. S4A), and we study the impact of the rise time Θ on the evolution of antimicrobial
resistance in a microbial population. In practice, our smooth function, shown in Fig. S4A, is
built using the error function erf(x) = (2/
√
pi)
∫ x
0 e
−u2 du, such that over each period of duration
T :
fS(t) = 1− 1
2
[
1 + erf
(
2
Θ
(
t− nT − T
2
))]
if nT +
T
4
≤ t < nT + 3T
4
, (S66)
fS(t) =
1
2
[
1 + erf
(
2
Θ
(t− nT − T )
)]
if nT +
3T
4
≤ t < (n+ 1)T + T
4
, (S67)
where n is a non-negative integer. In addition, we take fS(t) = 1 for 0 ≤ t ≤ T/4, i.e. we start
without antimicrobial at t = 0, and the first decrease of fitness occurs around t = T/2, in order
to be as close as possible to our binary approximation (see Fig. 1B). Finally, as an extremely
smooth case, we consider the case of a fitness fS modeled by a sine function of period T , with
the same initial condition and phase as our function with variable smoothness.
Figure S4: Robustness of the binary antimicrobial action model. (A) Smooth and
periodic fitness versus time relationship considered: Θ denotes the rise time. (B) Total time
tfC of full resistance evolution versus the period T for smooth alternations with different values
of Θ, and for the binary model. Data points correspond to the average of simulation results
(over 10 to 103 replicates), and error bars (often smaller than markers) represent 95% confidence
intervals. Parameter values: µ1 = 10
−5, µ2 = 10
−3, δ = 0.1, and N = 100.
We have performed stochastic simulations using the model described in the main text, but
with the fitness versus time relationship given in Eqs. S66-S67. Fig. S4 shows that for small
32
rise times Θ, the dependence on the period T of the total time tfC of full resistance evolution is
the same as with our binary approximation, provided that the rise time is much smaller than
the period, Θ ≪ T . Conversely, for small Θ satisfying Θ ≥ T , in which case our function is
very smooth even though the absolute rise time is short, the behavior of tfC is similar to that
obtained for the sine function. For larger values of Θ, namely Θ ≫ 10, the binary case is no
longer matched when Θ≪ T , and instead, a behavior intermediate between the binary case and
the sine case is observed. This intermediate behavior gets closer to that observed in the sine
case as Θ is increased.
These results can be rationalized as follows. When Θ is smaller than the relevant evolutionary
timescales identified in the main text (τdR, τ
f
R and 1/(Nµ1), the shortest ones being τ
d
R and τ
f
R
for Nµ1 ≪ 1), no relevant evolutionary process process can happen during a single smooth rise
or decay of the fitness. If in addition Θ is much smaller than the environmental timescale T ,
then the fitness versus time function is steep and effectively binary. However, if Θ is not much
smaller than T , then the function is smooth, and the binary approximation is inappropriate.
Finally, if Θ is longer than the shortest relevant evolutionary timescales (τdR, τ
f
R), then relevant
evolutionary processes can happen within a single smooth rise or decay of the fitness, and the
behavior is more complex. In a nutshell, our binary approximation is appropriate provided that
the rise time satisfies Θ≪ min(T, τdR, τ fR).
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